Intravenous Zanamivir Requests for Severely Ill Hospitalized Patients

For hospitalized influenza patients with suspected or known gastric stasis, gastric malabsorption, gastrointestinal bleeding, or for patients suspected or confirmed with oseltamivir-resistant influenza virus infection, intravenous zanamivir should be considered.

There are currently two ways to obtain IV zanamivir: enrollment in a clinical trial through a clinical site, or through a compassionate use request through Glaxo Smith Kline with FDA approval.

For information about potential enrollment in an IV zanamivir clinical trial, see: http://www.clinicaltrials.gov/ct2/show/NCT01014988?term=zanamivir&rank=3

To request IV zanamivir for compassionate use, the requesting clinician should first call GSK at:
GSK Clinical Support Help Desk:
Phone: 919-315-5215
Email: gskclinicalsupportHD@gsk.com
Availability is 7 days a week, 24 hours/day, including holidays.

GSK will provide information on obtaining IV zanamivir, assess eligibility for clinical trials, and provide the EIND forms that need to be completed for FDA approval if compassionate is requested for IV zanamivir for EIND is requested.

*The EIND paperwork does not need to be completed before contacting FDA and FDA granting an EIND request, so a requesting clinician should contact GSK first, and then quickly contact FDA.

To contact FDA:
To request FDA EIND approval for IV zanamivir during weekday work hours (8 AM - 4:30 PM EST), clinicians should call FDA at: 301-796-1500.
To request FDA EIND approval specifically for IV zanamivir after regular business hours, the requesting clinician should call: 301-796-9900 (nights or weekends).

Some selected references for IV zanamivir:


